Head-to-head evidence
LY03009 vs rotigotine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine · full Parkinson's Disease pipeline
LY03009
Developed by Luye Pharma Group
NCT04593511 · Phase 1 · status unknown
This open-label, single-dose pharmacokinetic study compared four different formulations of LY03009 against each other in healthy volunteers, but included no placebo or inactive control arm and no blinding. No results have been posted, and because every arm receives active drug in a different formulation, this design cannot demonstrate a treatment effect once results are available.
rotigotine · Neupro
Marketed by UCB
NCT00244387 · Phase 3 · completed
Although the registry reports a randomized, double-blind design with 506 participants, it lists no comparator arm, so the treatment cannot be evaluated against another treatment or placebo from the available record. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY03009's landscape · rotigotine's landscape